Amarin Corp Plc (AMRN)

[Biobillionair]

RAF-FDA is full of doctors that don't practice medicine, they were wrong to cancel high trig surrogate using a study of a different drug. If you can't understand this then your not smart enough to reason with, there's no argument you will accept.

July 2017 AACE & EAS

Both AACE and ESC/EAS guidelines have acknowledged this shortcoming and consider patients with triglycerides >200 mg/dL to be at substantially increased ASCVD risk. Furthermore, they recommend that fibrates may be considered in patients with triglycerides >200 mg/dL and HDL-C <40 mg/dL mg/dL as this may improve CV outcomes. While no randomized controlled trial has specifically proven this approach, there have been several post-hoc and pre-specified subgroup analyses of RCTs that support its utility in reducing the residual risk left behind after LDL-C lowering has been addressed.9 Because of this uncertainity, the ESC/EAS guidelines made this a somewhat weaker IIb recommendation with level of evidence C. The AACE guidelines, however, were more aggressive and gave this their strongest recommendation. Until we have further clinical trials to say otherwise, it is reasonable to at least consider fenofibrate therapy in patients who have elevated triglycerides, low HDL-C, and recurrent ASCVD events despite aggressive statin therapy.

The FDA used the above "logic" to rescind ANCHOR. If you classify this as "logic", then again you aren't getting it and never will.
http://www.acc.org/latest-in-cardiology/articles/2017/08/11/08/35/aace-and-eas-lipid-guidelines

The FDA was flat out wrong, new they were wrong, and did nothing...

Again the FDA repeats dangerous vioxx-like regulation mistakes that lead to real harm, this can not be allowed to go unpunished or it will reoccur.
BB